LABTWIN
14.12.2022 12:01:42 CET | Business Wire | Press release
Today, Royal DSM N.V., a global company specializing in health, nutrition, and sustainable living, and LabTwin GmbH, the leading voice and AI-powered digital lab assistant, announce a multi-year license and collaboration agreement. DSM will apply the newly acquired technology in several of their Science & Innovation laboratories globally. Together, we intend to transform how science is performed in research and application labs providing significant value through speeding up innovation cycles at DSM and its partners worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005030/en/
DSM partners with LabTwin to empower scientists with the latest voice and AI solutions. (Graphic: Business Wire)
“We are excited to see that LabTwin is already onboarded on multiple of DSM’s R&D premises globally with more than 100 scientists and technicians, and we are looking forward to supporting them further in their digital transformation journey,” said Magdalena Paluch, CEO of LabTwin.
LabTwin’s digital lab assistant enables hands-free data capture through voice notes or connected lab instruments while working at the bench and provides on-the-go access to safety or operational information. LabTwin also talks scientists through protocols and records any deviations or out of specification results. This data is then automatically structured by LabTwin’s deep learning capabilities and enriched with metadata. The digital assistant will form part of DSM’s wider digitalization strategy, including the full integration with DSM’s Electronic Lab Notebooks.
Willi Gottstein, Scientist and Project Manager at DSM explains “LabTwin has already become the digital assistant of many of our experimentalists, leading to better data and result tracking in the lab, FAIR data processing and more efficient reporting in the office. LabTwin significantly lowers the threshold to record observations leading to higher reproducibility of experiments and easier trouble-shooting.”. Hans Roubos, Director Digital Science and Technologies at DSM continues: “LabTwin offers us a Siri-like experience for the Lab with many options for further advancing our lab operations, from guiding our scientists through laboratory protocols to interacting with labware and storing data and observations in a smart, hands-free way”.
Both DSM and LabTwin shall provide more details on this exciting collaboration in the coming year.
Watch this short product tour video to learn more about LabTwin or follow us on LinkedIn.
LabTwin
LabTwin is creating the next generation of digital lab tools for smart labs, starting with the world's first voice-activated lab assistant. With LabTwin, scientists can collect data, access information, manage experiments and streamline documentation simply by talking. Using voice recognition and machine learning technology, LabTwin’s smart assistant simplifies data capture, structures valuable information, and provides suggestions to scientists in real-time so they can make more informed data-driven decisions. LabTwin is backed by BCG Digital Ventures and Sartorius. Its voice-powered assistant is used in chemical companies and in 7 of the Top20 Pharma around the world.
DSM – Bright Science. Brighter Living. ™
Royal DSM is a global science-based company active in health & nutrition. DSM is organized in three Business Groups: Food & Beverage, Health Nutrition & Care, and Animal Nutrition & Health. Our long-term success in serving these markets require innovations that are customer-focused, value-adding and differentiating and, at the same time, grounded in market insights as well as best-in-class launch execution capabilities. DSM and its associated companies deliver an annual net sales of about €10 billion with approximately 25,000 employees. More information can be found at www.dsm.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005030/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom